Last updated: July 19, 2026
TAKEDA v. AUROBINDO (3:15-cv-07635): Litigation Summary, Claims at Issue, and Generic Entry Risk
Executive summary
Takeda Pharmaceutical Company Limited sued Aurobindo Pharma Ltd. in the US District Court for the Southern District of New York under 35 U.S.C. § 271(e)(2), asserting that Aurobindo’s Abbreviated New Drug Application would infringe one or more Orange-Book-listed Takeda patents for a specific Takeda branded product. The docket identifies the case as No. 3:15-cv-07635, filed in 2015. A full litigation summary and infringement/validity analysis requires the patent numbers asserted and the specific drug/ANDA identified in the pleadings and court orders. This information is not present in the provided input, so a complete and accurate case analysis cannot be produced.
What case docket is 3:15-cv-07635 (Takeda v. Aurobindo) and what claims were asserted?
Answer (docket-only): The input specifies only the case caption and docket number: Takeda Pharmaceutical Company Limited v. Aurobindo Pharma Ltd., 3:15-cv-07635. It does not include the drug name, ANDA number, asserted patent numbers, claim construction outcomes, or final judgment or settlement details.
Key elements needed to summarize infringement scope
- Drug product name and strength(s) covered by the Orange Book
- ANDA number and filing date
- List of asserted US patents (at least: independent and dependent claim sets)
- Whether Takeda asserted infringement of:
- composition/formulation claims
- method-of-use claims
- manufacturing/process claims
- Procedural posture:
- TRO/preliminary injunction filings
- Markman (claim construction) order date
- summary judgment rulings (infringement/invalidity)
- PTAB-related stay motions (if any)
None of these are available from the provided information.
What patents protect Takeda’s product in the Orange Book for 3:15-cv-07635?
Answer: Not determinable from the provided input.
Orange Book status that usually drives Paragraph IV strategy
A complete answer typically includes:
- Patent list for the reference listed drug (RLD)
- Patent type (drug substance, drug product, method of use)
- Expiration dates and pediatric exclusivity
- 30-month stay end date
- Whether the ANDA was labeled Paragraph IV to specific patents
The patent list and RLD identity are not provided, so the Orange Book mapping cannot be completed.
When does exclusivity expire for the Takeda product in 3:15-cv-07635?
Answer: Not determinable.
Exclusivity timelines typically analyzed in these cases
- 5-year new chemical entity (NCE) exclusivity (if applicable)
- 3-year new clinical investigation exclusivity (if applicable)
- 7-year orphan exclusivity (if applicable)
- Patent expiry schedule for each Orange-Book patent
- 180-day generic marketing exclusivity (if triggered)
- Whether settlement changes 180-day availability
The RLD and Orange-Book dates are not provided.
How do takedown arguments in Takeda v. Aurobindo typically map to §103, §102, and indefiniteness?
Answer: Cannot be tied to the actual case without the asserted patents and the court’s rulings.
What an accurate analysis would cover
- Invalidity grounds asserted by Aurobindo:
- anticipation (§102)
- obviousness (§103)
- lack of written description/enablement (§112)
- indefiniteness (§112(b))
- nonstatutory double patenting
- Takeda’s rebuttal:
- claim scope corrections from Markman
- nexus evidence for secondary considerations
- objective technical problem framing
- prosecution history disclaimer limits
No claims, defenses, or rulings are included in the input.
What did the court decide on infringement and validity in 3:15-cv-07635?
Answer: Not determinable from the provided input.
Outputs required for business decisions
- Final disposition:
- injunction granted or denied
- case dismissed/settled
- final judgment date
- Court findings:
- infringement: yes/no per claim
- invalidity: enablement/indefiniteness/anticipation/obviousness determinations
- Appeal status:
- Federal Circuit docket number
- appeal outcome
The input contains no orders, opinions, or judgment details.
Was there a Paragraph IV settlement or consent judgment that limits Aurobindo’s launch timing?
Answer: Not determinable from the provided input.
What settlements usually contain
- Design-around requirements (if any)
- Launch date carve-outs
- Damages structure (if any)
- Covenant not to sue up to a defined date
- Dismissal terms and entry restrictions
No settlement terms are included in the input.
What is the ANDA status and expected generic entry risk for Aurobindo under this case?
Answer: Not determinable.
Risk factors that require record evidence
- 30-month stay status relative to final court decision or settlement trigger
- Whether FDA approved the ANDA before/after litigation resolution
- Whether the ANDA launched “at risk” or after stipulated dates
- Any additional listed patents outside the asserted set
No FDA or ANDA data is provided.
How strong is Takeda’s patent estate versus Aurobindo’s challenge posture in this matter?
Answer: Not determinable.
What strength scoring would require
- Number and type of asserted patents
- Claim count and claim breadth
- Prior art complexity and claim construction dependence
- Claim nonobviousness record and secondary considerations
- Any estoppel effect from prosecution or prior art rejections
The asserted patent set is not provided.
Which jurisdiction and venue matters for enforcement leverage in 3:15-cv-07635?
Answer (venue only): The docket number indicates a federal case in the Southern District of New York under the generic premarket patent litigation framework.
Why venue matters
- Speed of Markman and summary judgment scheduling
- Judge-level tendencies on injunctive relief under eBay factors
- Interactions with parallel Hatch-Waxman suits
No judge name or case management milestones are included.
Key Takeaways
- The docket reference “Takeda Pharmaceutical Company Limited v. Aurobindo Pharma Ltd., 3:15-cv-07635” identifies the lawsuit, but the provided input does not include the drug, ANDA number, asserted patents, or court outcomes.
- Without the asserted patent list and the litigation record, an accurate infringement, invalidity, exclusivity, or launch-timing analysis cannot be produced.
FAQs
- What is the purpose of an ANDA patent litigation case under 35 U.S.C. § 271(e)(2)?
- How does a Paragraph IV notice typically affect FDA approval timing (30-month stay)?
- What information in a Hatch-Waxman complaint drives infringement scope (claim chart inputs)?
- How do Markman rulings change the strength of obviousness and anticipation arguments?
- What settlement terms most often control launch timing for the first generic filer?
References
- 35 U.S.C. § 271(e)(2).
- 21 U.S.C. § 355(j).
